Acesion Pharma is aiming for developing more efficacious and safer drugs for the medical treatment of atrial fibrillation (AF).
The scientific background is based on the novel concept of treating AF by inhibiting the so-called SK channels. These are ion channels present in the heart where they are relevant for regulating the cardiac rhythm. Blocking this ion channel with a selective drug molecule constitutes a novel and promising target for developing improved treatment of AF.
Diness, J. G.; Skibsbye, L.; Jespersen, T.; Bartels, E. D.; Sørensen, U. S.; Hansen, R. S.; Grunnet, M. Effects on Atrial Fibrillation in Aged Hypertensive Rats by Ca2+-Activated K+ Channel Inhibition. Hypertension 2011, 57, 1129-1135.
Skibsbye, L.; Diness, J. G.; Sørensen, U. S.; Hansen, R. S.; Grunnet, M. The duration of pacing induced atrial fibrillation is reduced in vivo by inhibition of small conductance Ca2+ activated K+ Channels. J. Cardiovasc. Pharmacol. 2011, 57, 672-681.
Diness, J. G.; Sørensen, U. S.; Nissen, J. D.; Al-Shahib, B.; Jespersen, T.; Grunnet, M.; Hansen, R. S. Inhibition of small-conductance Ca2+-activated K+ channels terminates and protects against atrial fibrillation. Circulation Arrhythm. Electrophysiol. 2010, 3, 380-390.